-
Since 2022, a large number of pharmaceutical companies have joined the team to sell assets
Time of Update: 2022-05-02
For example, in mid-February, some industry sources said that Sandoz, a generic drug company owned by Novartis, may be sold to private equity firms Blackstone Group and Carlyle Group for $25 billion.
-
In the field of first-in-class, a large number of local pharmaceutical companies are actively deploying
Time of Update: 2022-05-02
In recent years, with the advancement of policies such as the reform of the drug review and approval system and the drug marketing authorization holder system, China's biopharmaceutical industry has continued to grow and develop, and has inspired a large number of local pharmaceutical companies to increase investment in research and development, improve innovation strength, and gradually change from Generic drugs such as me-too are upgraded to First-in-class innovative drugs .
-
Analyzing the advantages of the "Belt and Road" and talking about the possibility of generic drugs going overseas
Time of Update: 2022-05-02
On the other hand, with the encouragement and promotion of the "One Belt, One Road" policy, pharmaceutical companies will no longer export generic drugs to countries along the route alone, which can effectively reduce risks and improve the possibility of success and profitability .
-
Embarrassing 1.2 new Chinese medicines
Time of Update: 2022-05-02
” This point of view is a good description of the different research and development paths of traditional Chinese medicine compound preparations and innovative drugs 1.
2 new traditional Chinese medicines are approved in accordance with the current drug registration management measures.
-
Qilu, China Resources... siege 600 million painkillers!
Time of Update: 2022-05-02
Source: CDE official website, Minet database A few days ago, the CDE official website showed that the pregabalin capsules of Hunan Sailong Pharmaceutical Co.
Source: CDE official website, Minet database A few days ago, the CDE official website showed that the pregabalin capsules of Hunan Sailong Pharmaceutical Co.
-
Under the intensified competition in the generic drug market, improved drugs have become a new hot spot for research and development
Time of Update: 2022-05-02
In general, under the background of accelerated innovation and development of pharmaceutical companies, improved new drugs with obvious clinical advantages and less risk will usher in a "R&D outlet" with policy support .
-
Panoramic Interpretation of China's Clinical Trial Application Trends in 2021
Time of Update: 2022-05-02
During this period, the number of core clinical trials carried out in the United States has stabilized at more than 200 per year, while the core clinical development of Chinese companies has increased rapidly since 2017.
-
Another pharmaceutical company discloses 2021 annual performance forecast
Time of Update: 2022-05-02
The performance forecast released by GenScript Biotechnology shows that in fiscal 2021, the adjusted net profit of the group business (non-cell therapy business) excluding the subsidiary Legend Biotechnology was about US$48 million to US$51.
-
More than 900 companies were investigated, and 2 pharmaceutical machine companies received attention from more than 20 institutions
Time of Update: 2022-05-02
Among them, in view of the company's future business growth, Chutian Technology said that three years ago, the company has been deploying import substitution in the high-end market of vaccine products, and product performance and quality have been able to meet the needs of high-end customers .
-
Pharmaceutical companies are strengthening domestic substitution of upstream equipment, and the pharmaceutical machine industry may benefit
Time of Update: 2022-05-02
For this cooperation, the industry believes that, in addition to speeding up the integrated competitiveness of the research and development, production and sales of Kangfang biopharmaceuticals, it is also a manifestation of domestic innovative pharmaceutical companies strengthening the independent controllability of the supply chain and domestic substitution .
-
WuXi Junuo: The marketing application for the second indication of CD19 CAR-T was accepted by the State Food and Drug Administration
Time of Update: 2022-05-02
This is WuXi Junuo's second marketing authorization application for Benoda® and is expected to be the first cell therapy product approved in China for the treatment of patients with r/r FL .
-
The policy of speeding up the evaluation of new traditional Chinese medicines has detonated the market conditions, and the battle for innovative resources of traditional Chinese medicines has begun!
Time of Update: 2022-05-02
The "Guiding Opinions of the National Medical Security Administration and the State Administration of Traditional Chinese Medicine on Medical Insurance Supporting the Inheritance, Innovation and Development of Traditional Chinese Medicine" is one of the important factors that will detonate the performance of the entire traditional Chinese medicine industry in the secondary market by the end of 2021 and early 2022 .
-
Pharmaceutical companies are in hot pursuit of innovation and R&D, with more than 20 new applications for Category 1 drug trials added within a week
Time of Update: 2022-05-02
Coincidentally, the marketing application of the new anti-tumor drug MET inhibitor Gumetinib, jointly developed by Haihe Pharmaceuticals and the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, has also been accepted by the State Food and Drug Administration and is being announced for priority review .
-
The abuse of antibiotics at the grassroots level is more than the harm of the abuse of antibiotics?
Time of Update: 2022-05-02
Moxifloxacin, as a fourth-generation quinolone broad-spectrum antibacterial drug, has been mainly used in large hospitals for patients with pulmonary infection in recent years, that is, when ordinary antibiotics are ineffective .
But this patient was only on moxifloxacin for a common upper respiratory tract infection .
-
More than 240 pharmaceutical companies have disclosed performance forecasts, with dazzling net profits concentrated in the fields of vaccines and testing
Time of Update: 2022-05-02
. In addition to Zhifei Bio and CanSino, the net profit of vaccine companies such as Olin Bio and Kangtai Bio is also expected to increase significantly year-on-year in 2021.
-
The centralized procurement of dental implants is already in the air, will the price be greatly reduced in the future?
Time of Update: 2022-05-02
After the National Medical Insurance Bureau clarified the centralized procurement of dental implants, the market has also expressed concern about the attitude of related dental companies .
-
78 drugs from 21 pharmaceutical companies took the initiative to cut prices, with a drop of over 60%!
Time of Update: 2022-05-02
On February 21, the Yunnan Provincial Centralized Drug Purchasing Platform issued a public announcement about companies applying for price reductions .
7ml:100mg and 5ml:30mg specifications of Huiyu Pharmaceutical's paclitaxel injection have been greatly reduced in price, of which the 16.
-
Intellia and Regeneron Announce Latest Phase 1 Clinical Trial Data of NTLA-2001
Time of Update: 2022-05-02
The results showed that all doses administered were well tolerated, with mean 86% and 93% reductions in serum levels of the target protein in the two highest dose groups, respectively .
-
The transformation of pharmaceutical companies is accelerating and forcing the upgrading of production equipment, and pharmaceutical machine companies need to fight a "cooperation war"
Time of Update: 2022-05-02
For example, last year, Hongdou Group's anti-tumor high-end complex preparation smart factory project with a total investment of 520 million yuan has officially started .
There is also a smart medical equipment manufacturing project invested by a pharmaceutical machine company of 1 billion yuan.
-
Dozens of executives of pharmaceutical companies have left this year, and traditional Chinese medicine companies account for the majority
Time of Update: 2022-05-02
According to the report, Li Weijun applied to resign as the company's director, vice president and member of the compensation and appraisal committee of the board of directors due to personal reasons, and at the same time resigned from all positions held in the company's subsidiaries .
